Management of the patient and family with neurofibromatosis 2: a consensus conference statement
- PMID: 16147576
- DOI: 10.1080/02688690500081206
Management of the patient and family with neurofibromatosis 2: a consensus conference statement
Abstract
A consensus conference on neurofibromatosis 2 (NF2) was held in 2002 at the request of the United Kingdom (UK) Neurofibromatosis Association, with particular emphasis on vestibular schwannoma (VS) surgery. NF2 patients should be managed at specialty treatment centres, whose staff has extensive experience with the disease. All NF2 patients and their families should have access to genetic testing because presymptomatic diagnosis improves the clinical management of the disease. Some clinical manifestations of NF2, such as ocular abnormalities, can be detected in infancy; therefore, clinical screening for at-risk members of NF2 families can start at birth, with the first magnetic resonance (MRI) scan at 10-12 years of age. Minimal interference, maintenance of quality of life, and conservation of function or auditory rehabilitation are the cornerstones of NF2 management, and the decision points to achieve these goals for patients with different clinical presentations are discussed.
Similar articles
-
Neurofibromatosis 2--a family journey.Can J Neurosci Nurs. 2009;31(4):7-14. Can J Neurosci Nurs. 2009. PMID: 20085115
-
[Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].Lijec Vjesn. 2006 Sep-Oct;128(9-10):309-16. Lijec Vjesn. 2006. PMID: 17128670 Review. Croatian.
-
Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?Clin Genet. 2007 Apr;71(4):354-8. doi: 10.1111/j.1399-0004.2007.00778.x. Clin Genet. 2007. PMID: 17470137
-
Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2.J Med Genet. 2005 Dec;42(12):903-6. doi: 10.1136/jmg.2005.031302. Epub 2005 Apr 14. J Med Genet. 2005. PMID: 15831594 Free PMC article. Review.
-
Molecular biology of vestibular schwannomas.Methods Mol Biol. 2009;493:163-77. doi: 10.1007/978-1-59745-523-7_10. Methods Mol Biol. 2009. PMID: 18839347
Cited by
-
Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.Int J Mol Sci. 2021 May 29;22(11):5850. doi: 10.3390/ijms22115850. Int J Mol Sci. 2021. PMID: 34072574 Free PMC article. Review.
-
Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines.Cancers (Basel). 2019 Aug 4;11(8):1114. doi: 10.3390/cancers11081114. Cancers (Basel). 2019. PMID: 31382694 Free PMC article.
-
Multifocality in neurofibromatosis type 2.Neuro Oncol. 2015 Apr;17(4):481-2. doi: 10.1093/neuonc/nou338. Epub 2014 Dec 23. Neuro Oncol. 2015. PMID: 25537020 Free PMC article. No abstract available.
-
Multiple primary cranio-spinal tumours in a 13-year-old female with neurofibromatosis type 2 management strategy.Childs Nerv Syst. 2011 Jan;27(1):175-8. doi: 10.1007/s00381-010-1238-3. Epub 2010 Jul 27. Childs Nerv Syst. 2011. PMID: 20661577 Free PMC article.
-
Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.J Med Genet. 2006 Apr;43(4):289-94. doi: 10.1136/jmg.2005.036319. Epub 2005 Sep 9. J Med Genet. 2006. PMID: 16155191 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous